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Nitric oxide and bone
ROB J. VAN’T HOF & STUART H. RALSTON Department of Medicine and Therapeutics, University of Aberdeen,
Aberdeen, UK
SUMMARY
Nitric oxide (NO) is a free radical which has important effects on bone cell function. The endothelial
isoform of nitric oxide synthase (eNOS) is widely expressed in bone on a constitutive basis, whereas
inducible NOS is only expressed in response to inflammatory stimuli. It is currently unclear whether
neuronal NOS is expressed by bone cells. Pro-inflammatory cytokines such as IL-1 and TNF cause
activation of the iNOS pathway in bone cells and NO derived from this pathway potentiates
cytokine and inflammation induced bone loss. These actions of NO are relevant to the pathogenesis
of osteoporosis in inflammatory diseases such as rheumatoid arthritis, which are characterized
by increased NO production and cytokine activation. Interferon gamma is a particularly
potent stimulator of NO production when combined with other cytokines, causing very high
concentrations of NO to be produced. These high levels of NO inhibit bone resorption and
formation and may act to suppress bone turnover in severe inflammation. The eNOS isoform seems
to play a key role in regulating osteoblast activity and bone formation since eNOS knockout mice
have osteoporosis due to defective bone formation. Other studies have indicated that the NO
derived from the eNOS pathway acts as a mediator of the effects of oestrogen in bone. eNOS also
mediates the effects of mechanical loading on the skeleton where it acts along with prostaglandins,
to promote bone formation and suppress bone resorption. Pharmacological NO donors have been
shown to increase bone mass in experimental animals and preliminary evidence suggests that these
agents may also influence bone turnover in man. These data indicate that the L-arginine/NO
pathway represents a novel target for therapeutic intervention in the prevention and treatment of
bone diseases.
INTRODUCTION
Nitric oxide (NO) is a free radical involved in the regulation of
many physiological processes, such as vascular relaxation,1
neurotransmission, platelet aggregation and in immune
regulation.2 Over recent years it has become apparent that
NO has important effects on bone cell function and here we
review the role of the L-arginine–NO pathway as a regulator of
bone remodelling in health and disease.
Bone is a complex tissue composed of several cell types
which is continuously undergoing a process of renewal and
repair termed ‘bone remodelling’ (Fig. 1). The two major
cell types responsible for bone remodelling are osteoclasts,
which resorb bone, and osteoblasts, which form new bone.
Osteoclasts are multinucleated cells of haemopoietic origin,
which differentiate from precursors in the monocyte/macro-
phage lineage, in response to co-ordinated expression of
lineage-specific regulatory molecules including c-fos, M-CSF
RANK (receptor activator of NFkB), RANK ligand
(RANKL) and osteoprotegerin (OPG).3 Osteoblasts, on the
other hand, are cells of mesenchymal origin which differentiate
from bone marrow stromal cells in response to activation of
the transcription factor Cbfa1.4 During the bone remodelling
cycle, old or damaged bone is removed by osteoclasts, by
the secretion of acid and proteolytic enzymes onto the bone
surface. Subsequently the osteoclasts migrate away from the
area of bone undergoing resorption and undergo apoptosis.
They are replaced by osteoblasts, which lay down new bone
matrix in the form of osteoid. Later, the osteoid becomes
calcified to form mature bone. During bone formation, some
osteoblasts become embedded within the bone matrix, and
differentiate into osteocytes, a third cell type unique to bone.
Osteocytes interconnect with one another and with cells on the
bone surface through a series of long cytoplasmic processes
that run through cannaliculi in the bone matrix. It is thought
that osteocytes act as sensors of mechanical stress in the
skeleton, by detecting and responding to changes in fluid flow
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which run through cannaliculi in bone. Bone remodelling is
regulated by several systemic hormones, such as parathyroid
hormone (PTH), 1,25 dihydroxyvitamin D3, sex hormones and
calcitonin, as well as by local factors such as NO, prostaglan-
dins, growth factors and cytokines. It is currently believed that
many of the factors which regulate bone remodelling do so by
influencing local expression of RANK, RANKL and OPG,5–7
which together form a paracrine system that plays an essential
role in regulating osteoclast differentiation and function
(Fig. 1, inset).3,8
NITRIC OXIDE SYNTHESIS AND REGULATION
NO is generated by the nitric oxide synthase enzymes (NOS)
from molecular oxygen and the terminal guanidino nitrogen of
the amino acid L-arginine, yielding L-citrulline as a coproduct.9
This reaction can be inhibited by substituted arginine ana-
logues such as L-NG-monomethyl arginine (L-NMMA) and
L-nitro-arginine-methyl ester (L-NAME). NO can also be gene-
rated nonenzymatically from nitrite in the acid environment of
the stomach10 and pharmacologically by compounds such as
organic nitrates (e.g. nitro-glycerine) and sodium nitro-
prusside,9 which are used clinically as vasodilators (Fig. 2).
NO can be measured by chemiluminescence9 and by the use
of special NO-sensitive electrodes,11 but since the half-life of
NO is in the order of seconds, these direct measurements are
difficult. NO rapidly reacts with oxygen to yield the stable
metabolites nitrate (NO3) and nitrite (NO2), and NO produc-
tion can be more easily assessed indirectly by measuring
accumulation of NO3 and NO2 using the Griess reaction.
9 The
amount of accumulated NO3 and NO2 does not always reflect
the amount of NOS enzyme present, as enzyme activity may be
limited by availability of its cofactors. To measure the amount
of NOS enzyme, the conversion of radiolabelled L-arginine to
L-citrulline is measured using an in vitro assay.9
Three isoforms of NOS have been identified so far; a
neuronal form (nNOS or NOS1),12 an endothelial form (eNOS
or NOS3)13 and an inducible form (iNOS or NOS2).14 Both
eNOS and nNOS are constitutively expressed at low levels in
their tissues of origin and their activity is mainly regulated by
changes in free intracellular Ca++ concentration ([iCa++]).9
However, it has recently been shown that eNOS can also be
activated by certain cytokines through the IP3/akt pathway.
The protein kinase akt phosphorylates the eNOS protein at
serine 1177 and this activates the enzyme.15 Little is known of
the factors that regulate nNOS expression at a transcriptional
level, but it has been shown that the eNOS gene promoter
contains several oestrogen response elements and shear-stress
responsive elements.16 Consistent with this, increases in eNOS
mRNA have been found in endothelial cells exposed to shear
stress17 or oestrogen.18
Figure 2. The L-arginine–nitric oxide pathway. NO is synthesized from
L-arginine and molecular oxygen by the NOS group of enzymes. In
inflammation, cytokines such as IL-1 and TNF are upregulated. The
cytokines induce expression of the inducible NOS (iNOS) gene, leading
to synthesis of the iNOS enzyme, which produces nitric oxide (NO)
from L-arginine. NO can also be produced by pharmacological NO
donors such as SNAP. NO is a very reactive molecule and rapidly
reacts with oxygen to form nitrite and nitrate.
Figure 1. The bone remodelling cycle. The bone remodelling cycle of resorption, reversal and bone formation is responsible for
renewal and repair of old and damaged bone (main panel). Osteoclasts differentiate from haemopoetic precursors in the monocyte
lineage in response to activation of RANK, by its ligand RANKL, expressed on stromal cells (inset). This interaction is blocked by
OPG which acts as a decoy receptor for RANKL. Osteoblasts differentiate from mesenchymal precursors in bone marrow in response
to activation of the osteoblast-specific transcription factor Cbfa1.
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Regulation of iNOS mainly takes place at the level of
gene transcription. Transcription of the iNOS gene is activated
by pro-inflammatory cytokines such as interleukin-1 (IL-1),
tumour necrosis factor alfa (TNFa), gamma interferon
(cIFN) and endotoxin, whereas glucocorticoids and the anti-
inflammatory cytokines IL-4, IL-10 and TGFb are inhibitory.2
Sequence analysis of the human iNOS promoter has shown
substantial differences from the murine promoter.19 These
differences are probably responsible for differences in the
ease with which cytokines can induce NO production in dif-
ferent species.20 Recently Sunyer et al.21 have shown that
chicken osteoclasts can be induced to express iNOS, but that
this requires elevated [iCa++] and activation of PKC, rather
than stimulation with cytokines.
Different cell types differ in their ability to produce NO
after cytokine stimulation. Human primary osteoblast and
hepatocyte cultures require combinations of two or three
cytokines for a significant induction of NO synthesis,22,23
whereas human chondrocytes can be induced by single
cytokines such as IL-1 and TNF to produce NO.24,25 In
all cell types, however, combinations of cytokines are
generally more potent inducers of NO than single cyto-
kines.22,24,26
The iNOS pathway is thought to be capable of generating
much larger quantities of NO (nanomolar range) over a more
prolonged time frame than the constitutive NOS (cNOS)
enzymes (picomolar concentrations).2,27 However, because
iNOS activity depends on transcription, response to external
stimuli is not as rapid as that of cNOS (hours rather than
seconds).
MECHANISMS OF NO ACTION
Nitric oxide is a highly reactive molecule, and because of this
has many potential molecular targets. In vascular smooth
muscle and platelets, NO binds to the haem moiety of soluble
guanylyl cyclase (sGC)9 thus increasing the enzyme activity.
The resulting elevation in cGMP levels causes activation of a
cascade of cGMP dependent protein kinases, which mediate
smooth muscle relaxation, and inhibition of platelet adhesion.
Interestingly, the conformational changes induced by binding
of NO to the haem moiety of the NOS enzymes inhibit enzyme
activity, thereby providing an autoregulatory feedback loop by
which increased NO levels limit NO production.28
Other biological effects of NO are mediated by its ability to
react with sulphydryl residues and iron-sulphur centres in
proteins. The effect on iron-sulphur centres is thought to be
responsible for the inhibitory effect of high NO concentrations
on cell growth via interaction with mitochondrial aconitase,
a critical enzyme in the Krebs cycle.9
Recently, Landers et al.29–31 have shown that the small
GTPase p21ras is another molecular target for NO. NO nitro-
sylates the cysteine residue 118 (Cys118) of p21ras, resulting
in activation of GTPase activity and stimulation of the
map kinase and NFkB signal transduction pathways.
NO can also react with oxygen-derived free radicals such as
superoxide anions to form highly reactive molecules such as
the peroxynitrite anion and the hydroxyl radical.9 Production
of such toxic moieties may contribute to the tissue damage
that is a characteristic feature of an inflammatory response, by
inducing lipid peroxidation.32
The molecular targets for NO action in bone cells are
poorly understood. Initially it was thought that the inhibitory
effects of NO on osteoclastic bone resorption were mediated
by a cGMP independent mechanism,26,33 but evidence has
recently been presented to suggest that cGMP dependent
pathways may also be involved.34
EXPRESSION OF NOS ISOFORMS IN BONE
Recent data from several groups have shown that ecNOS is
widely expressed on a constitutive basis in bone marrow
stromal cells, osteoblasts, osteocytes and osteoclasts.35–37
Two studies have failed to detect nNOS expression in
cultured bone derived cells and in bone36,38 although expres-
sion of nNOS mRNA has been detected in bone by the reverse
transcription-polymerase chain reaction (RT-PCR).36 A more
recent study using a different antibody has, however, shown
evidence of nNOS protein expression in bone lining cells and in
osteocytes.39
Expression of iNOS has been observed in foetal bone,40
suggesting a role in skeletal development, but iNOS does not
appear to be expressed constitutively in normal adult bone.36,39
Expression of iNOS can be induced in osteoblasts and bone
marrow cells in vitro by stimulation with pro-inflammatory
cytokines and/or endotoxin however.22,41–43 It is currently
unclear whether osteoclasts are able to express iNOS. Our own
studies have failed to detect iNOS protein or mRNA in
cultured osteoclasts36 and studies in bone marrow cocultures
show that the majority of cytokine-induced NO derives from
osteoblasts.43 Nonetheless, weak iNOS expression has been
detected by other workers in osteoclasts in vivo39 and in
preosteoclastic cell lines in vitro.35
EFFECTS OF NO ON BONE RESORPTION
There is good evidence to suggest that NO has biphasic effects
on osteoclastic bone resorption. Low concentrations of NO
have been shown to potentiate IL-1 induced bone resorption,
based on the observation that NOS inhibitors inhibit IL-1
induced bone resorption in vitro.42 Constitutive production of
NO within osteoclasts has been suggested to be essential for
normal osteoclast function, based on the observation that NOS
inhibitors inhibit activity and motility of isolated osteoclasts.35
Nonetheless, examination of bones from animals with iNOS or
eNOS deficiency has shown no major defect in bone resorption
under physiological conditions, which suggests that these
isoforms are not essential for osteoclast formation or activity.
Accumulating evidence suggest that the iNOS pathway plays
an important role in cytokine and inflammation induced bone
loss however. Inflammation induced osteoporosis has been
shown to be mediated in part by activation of the iNOS
pathway44 and recent studies have shown that activation of the
iNOS pathway is essential for IL-1-stimulated bone resorption,
both in vivo and in vitro.45 The mechanism by which iNOS
promotes IL-1 induced bone resorption has been investigated
in cocultures of normal osteoblasts with iNOS-KO osteoclast
precursors. These studies have shown that IL-1 primarily acts
on osteoblasts to increase NO synthesis by activation of the
iNOS pathway and that this in turn promotes nuclear
translocation of the transcription factor NFkB in osteoclast
progenitors. Whilst osteoclast progenitors from iNOS deficient
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animals also show NFkB activation in response to IL-1, the
response is transient, implying that NO has a key role to play in
sustaining NFkB activation in osteoclast precursors.45
High concentrations of NO inhibit osteoclast formation
and activity. Experiments using cell and organ cultures have
shown that IFNc in combination with IL-1 and/or TNFa
strongly induces iNOS expression, leading to very high levels of
NO that inhibit bone resorption.35,41,42,46 These high NO
concentrations have been shown to be responsible for the
inhibitory effect of IFNc on IL-1 and TNFa stimulated bone
resorption.41,42 The inhibitory effect of high levels of NO
appear to be due to the inhibition of both osteoclast formation
and activity47 and NO-induced apoptosis of osteoclast
progenitors.47
A possible mechanism for the inhibition of osteoclast
activity by NO is the modification of cathepsin K. Cathepsin K
is highly expressed in osteoclasts and plays a key role in the
bone resorption mechanism, since it degrades bone collagen.
NO and several NO donors have been shown to inhibit the
activity of purified cathepsin K, although the modification of
the protein does not seem to involve nitrosylation, but rather
oxidation of thiol moieties.48
EFFECTS OF NO ON BONE FORMATION
Nitric oxide appears to have biphasic effects on osteoblast
activity. Studies in vitro have indicated that the small amounts
of NO which are produced constitutively by osteoblasts may
act as an autocrine stimulator of osteoblast growth and
cytokine production.49 Whilst some investigators have shown
that slow release NO donors stimulate osteoblast growth and
differentiation in vitro,34,50,51 other workers reported that NO
donors and NOS inhibitors had little effect on osteoblast
growth or differentiation, except at high concentrations where
inhibitory effects were observed.22,37 The most compelling
evidence supporting a role for NO in osteoblast function
derives from studies in eNOS knockout animals. Two groups of
investigators have reported major defects in bone formation
and osteoblast activity both in vivo and in vitro in eNOS
deficient animals and a reduced anabolic response to
exogenous oestrogen. The molecular mechanisms responsible
for this remain to be defined, but indicate the existence
of an important interaction between eNOS and the molec-
ular pathways involved in osteoblast differentiation and
function.50,52,53
High concentrations of NO, such as those observed after
stimulation with pro-inflammatory cytokines, have potent
inhibitory effects on osteoblast growth and differentiation,
however.22,34,54 Recent evidence suggests that this may be
partly due to pro-apoptotic effects of NO on osteoblasts,55,56
and that these effects are mediated in part by cGMP.34 This
observation may explain the inhibitory effects of pro-
inflammatory cytokines on bone formation and the reduced
bone formation which has been detected in conditions
associated with cytokine activation57,58 and in the animal
model of inflammation-mediated osteopenia.44,59,60
OESTROGEN, NO AND BONE
Oestrogen stimulates eNOS activity and mRNA levels in
endothelial cells18 and osteoblasts,61 raising the possibility that
NO derived from the eNOS pathway plays a role in mediating
the effects of sex hormones in bone. In keeping with this
hypothesis, Wimalawansa et al.62,63 have shown that NOS
inhibitors abolished the protective effect of oestrogen on bone
in ovariectomised rats, whereas in the same studies, the NO
donor nitro-glycerine was almost as effective as oestrogen in
preventing ovariectomy induced bone loss.62,63 Furthermore,
studies by Armour et al. showed that the anabolic effects of
oestrogen on bone formation were blunted in eNOS-knockout
mice.52 Taken together, these findings indicate that both the
anti bone resorptive and anabolic effects of oestrogen on bone
may be mediated in part by NO.
NO AND MECHANICAL STRESS
Several groups have shown that NO synthesis can be induced in
osteoblasts and osteocytes by mechanical strain and shear
stress. These stimuli cause rapid but transient increases in the
production of NO and prostaglandins by bone-derived cells
and organ cultures.64–67 The high concentrations of NO
induced by these stimuli may augment bone gain by inhibiting
the bone resorbing actions of the prostaglandins.26 The fact
that osteocytes and osteoblasts under noninflammatory con-
ditions only express the ecNOS isoform, taken together with
the rapid induction of NO by shear stress and mechanical strain
synthesis points to a role for the ecNOS isoform rather than
iNOS.65,66 It has also been reported that osteocytes show a
greater increase in NO-production as the result of mechanical
loading than osteoblasts, supporting the hypothesis that
osteocytes are the principal sensors and effectors of mechanical
stress in bone.
NO AND INFLAMMATORY DISEASE
Nitrate levels are elevated in urine and serum of patients
suffering from rheumatoid arthritis (RA),68,69 and even higher
levels have been detected in the synovial fluid,70 suggesting that
the inflamed joint is the source of the NO. Furthermore, NO
levels are higher in patients with active disease, than in those
with quiescent disease,71 and NO levels fall with prednisolone
treatment,69 indicating an association between disease status
and NO production.
Considerable amounts of nitrosylated protein have been
detected in the synovial fluid of RA patients, but not in
osteoarthritis (OA) patients.72,73 It has been suggested that
nitrosylation may be an important cause of joint damage in RA
and the effects of several anti-inflammatory drugs on
nitrosylation levels have recently been studied.74
The iNOS enzyme is readily detected in synovium and
cartilage of RA patients, is expressed at lower levels in OA but
is virtually absent from normal synovium and cartilage.75–77
Synovial cells and chondrocytes are able to produce high levels
of NO upon cytokine stimulation in vitro,24,75,78 and the iNOS
expression is associated with apoptosis of synovial cells
and chondrocytes.76,79,80 One mechanism by which NO can
induce apoptosis is by upregulating expression of the tumour
suppressor gene p5381 and p53 overexpression has been
observed in the synovial lining cells in RA.82 In vitro, NO
has been shown to be a potent stimulator of chondrocyte
apoptosis83 and this may contribute to the cartilage damage
observed in RA. Furthermore, cytokine induced NO stimulates
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the production of matrix metallo-proteinases in chondro-
cytes,71 which may lead to further destruction of the cartilage,
and it has been shown that the protective effects of IL-4 are at
least in part mediated by suppression of NO synthesis.84
As mentioned earlier, NO potentiates cytokine induced
bone resorption42 and high levels can also inhibit bone
formation.22,34,42,42,54 Therefore, NO produced within the
inflamed joint may contribute to the peri-articular bone loss
observed in RA. In an experimental model of inflammation
induced bone loss, NOS-inhibitors reduced the bone loss
observed.44 Further experiments using iNOS-knockout mice
indicate that iNOS is the isoform involved in the inflammatory
bone loss.60 Histomorphometric analysis of bones from normal
animals with inflammation induced bone loss showed a
profound depression of bone formation44 and evidence of
osteoblast apoptosis. These changes were not observed in
iNOS knockout animals, which suggests that iNOS activation
may contribute to inflammation induced osteoporosis by sup-
pressing bone formation and promoting osteoblast apoptosis
(K. J. Armour et al. unpublished results).
It has been shown that NOS inhibitors can reduce the
severity of arthritis in animal models of arthritis.85–88 Whilst
this suggests that NOS inhibitors may have an important
clinical use in the treatment of inflammatory disease in humans,
no human studies have been published so far.
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